Distinct Healthcare Holdings Limited

Date of Prospectus: January 29, 2026

Distinct Healthcare Holdings IPO: Key Details, Financials, Cornerstone Investors, Growth Strategy, and Listing Outlook

Distinct Healthcare Holdings Limited is launching its highly anticipated IPO on the Main Board of the Stock Exchange of Hong Kong, aiming to position itself as a transformative healthcare innovator. This article provides an in-depth, investor-focused analysis of the IPO snapshot, financial metrics, cornerstone investor participation, deal structure, sector outlook, risk factors, and listing prospects—based strictly on the disclosed details.

IPO Snapshot: Distinct Healthcare Holdings Limited

Distinct Healthcare Holdings Limited is set to list on the Main Board of the Stock Exchange of Hong Kong, targeting a growth-driven story with advanced AI healthcare investments and expansion plans.

• IPO Symbol: Not explicitly provided
• Offer Price Range: HK\$57.70 – HK\$66.60 per share
• Total Offer Size: 4,750,000 Offer Shares (Global Offering), excluding the Over-allotment Option
• Post-IPO Outstanding Shares: 64,384,350 shares (assuming Over-allotment Option is not exercised)
• Expected Market Capitalization: Approximately HK\$3,714.98 million (min), HK\$4,001.49 million (mid), HK\$4,288.00 million (max), depending on final pricing
• Offer Period: Applications open at 9:00 a.m. on Thursday, January 29, 2026, and close at 11:30 a.m. on Tuesday, February 3, 2026
• Listing Date: Expected on Friday, February 6, 2026
• Over-allotment Option: Up to 712,500 additional shares (15% of the initial offer) may be issued to cover over-allocations

Use of Proceeds: Growth-Driven Allocation

Distinct Healthcare Holdings demonstrates a clear growth orientation with significant proceeds earmarked for technology, expansion, and operational efficiency.

• Total Net Proceeds (mid-point): HK\$219.1 million
• Advanced AI Technologies: 35% (approx. HK\$76.7 million) for AI-driven healthcare delivery, operational efficiency, talent pool development, strategic collaborations, and IT systems enhancement
• Expansion of Healthcare Network: 25% (approx. HK\$54.8 million) for expansion and upgrades of healthcare institutions and clinics
• Research & Talent Development: 20% (approx. HK\$43.8 million) for medical research, professional training, and recruitment
• Working Capital & Operations: 20% (approx. HK\$43.8 million) for general working capital and operational needs

This allocation profile strongly signals growth, innovation, and a commitment to sector leadership.

[[36]]

Placement & Issuance Breakdown

The IPO consists of a diversified offering structure with distinct participation tranches.

• Hong Kong Public Offering: 475,000 shares (10%)
• International Offering: 4,275,000 shares (90%)
• Cornerstone Investors: 1,446,100 shares at mid-point pricing (approx. 30.44% of the offer and 2.25% of post-IPO shares)
• ESOP/Employee Incentives: 5,000,000 RSUs reserved, representing 7.76% of pre-IPO capital

Cornerstone allocations indicate confidence from strategic health sector and technology players.

[[435]]

[[435]]

Investor Participation & Book Quality

Cornerstone and Pre-IPO anchor investors include Health Vision, Kingmed Diagnostics, Mininglamp Technology, Galaxy Dynasty, Image Frame (Tencent subsidiary), Matrix Partners, H Capital, Waterwood, and Tiantu Entities.

• Cornerstone Investors: Allocated 1,446,100 shares at IPO, locked-up for a designated period
• Pre-IPO Investors: Significant allocations and prior investments, with strategic lock-ups and conversion of preferred shares into ordinary shares
• Book Quality: Strong institutional and strategic participation, high public float (approx. 29.98%), and free float (approx. 11.47% held by public and not restricted)
• Employee RSUs: 5,000,000 RSUs reserved for employee incentives
• No mention of oversubscription rates or retail/institutional subscription multiples

The depth and diversity of cornerstone and strategic investors, along with healthy public float, suggest robust listing day demand and support.

[[226]], [[227]], [[220]], [[216]]

Deal Parties & Structure

The IPO is managed by leading investment banks and sponsors, with stabilization mechanisms in place.

• Joint Sponsors: Haitong International Securities Company Limited, SPDB International Capital Limited
• Global Coordinators/Bookrunners/Lead Managers: Same as above (Joint Overall Coordinators)
• Underwriters: Named in the Underwriting section, including Hong Kong Underwriters and International Underwriters
• Financial Adviser: Arta Corporate Advisory Limited
• Stabilization/Greenshoe: Over-allotment option for up to 712,500 shares (15%) exercisable for 30 days post-offer
• Underwriting Commission: 3% fixed fee, up to 1% discretionary fee

Deal structure ensures strong institutional support and stabilization, which could bolster listing day price performance.

[[115]], [[479]], [[671]]

Company Overview: Business Model, Revenue Streams, Products & Market Position

Distinct Healthcare Holdings operates as a leading integrated healthcare provider, focused on developing and operating advanced healthcare institutions with a strong emphasis on technology-driven medical services.

• Business Model: Operates healthcare institutions, leverages AI and digital platforms, offers medical services to private and public clients
• Key Revenue Streams: Patient services, institutional contracts, technology-driven healthcare solutions
• Customer Segments: Individuals, institutions, strategic partners
• Geographies: China-centric with regional expansion plans
• Industry Size: Not numerically specified, but sector is defined as healthcare and medical services, with growth driven by demand for innovative solutions and technology
• Competitive Advantages: Brand strength, AI-driven operational efficiency, strategic partnerships, strong management

Management Team: Led by experienced directors and senior management with relevant sector expertise. Names and roles are disclosed in the Directors and Parties Involved section.

[[224]], [[125]], [[220]], [[453]]

Financial Health: Revenue, Margins, Profitability & Key Ratios

Distinct Healthcare Holdings demonstrates improving financial performance and margin expansion, transitioning from losses to profitability over the review period.

[[31]], [[392]]

Revenue: RMB958.6 million for year ended December 31, 2024, exceeding HK\$500 million, meeting listing test criteria

Profitability: Turning positive in 2024 and forecasted to improve in 2025

Working Capital: Sufficient for 12 months post-listing as per Directors’ confirmation

Capex: Significant investments anticipated in technology and expansion

Trends, Timing & Market Environment

Distinct Healthcare Holdings is well-positioned to benefit from sectoral growth, digitalization, and technology adoption in healthcare.

• Sector Trends: Healthcare sector in China is undergoing rapid transformation driven by digital, AI, and operational innovation
• Historical Demand Drivers: Growing demand for advanced healthcare services, regulatory support for innovation, increasing patient base
• Timing: Offer period is January 29, 2026 – February 3, 2026; Listing Date February 6, 2026
• Macroeconomic Environment: Favorable as per prospectus, with supportive regulatory filing (CSRC approval completed September 16, 2025)
• Recent Developments: RSU Scheme adopted, fresh capital infusions from strategic investors, and substantial Pre-IPO investments

Sector dynamics and regulatory clarity suggest positive conditions for the IPO.

[[115]], [[220]], [[453]]

Risk Factors

The company highlights several key risk exposures with quantified details:

• Legal and Regulatory Risk: Subject to healthcare sector regulations and CSRC listing trial measures
• Customer and Supplier Concentration: Not quantified, but referenced as potential risks
• FX and Macroeconomic Exposure: Subject to changes in interest rates, foreign exchange rates, and overall market trends
• Related-Party Transactions: Pre-IPO investor relationships and cornerstone allocations
• Operational Risks: Technology integration, talent recruitment, expansion execution
• Lock-up and Shareholder Structure Risks: Significant lock-up periods for Pre-IPO and cornerstone investors; public float and free float above minimum listing requirements

No major legal claims or adverse changes reported as of the Latest Practicable Date.

[[63]], [[107]], [[670]], [[674]]

Growth Strategy

Distinct Healthcare Holdings is focused on aggressive sector expansion, technology leadership, and talent development.

• AI Technology Investment: Dedicated allocation for AI, digital transformation, and operational efficiency
• Healthcare Network Expansion: Upgrades and new clinics
• R&D and Talent: Medical research, professional training, recruitment
• Employee Incentives: RSU Scheme for talent retention and motivation
• Capex Pipeline: Funded from IPO proceeds, with clear allocations

All strategies are well-aligned with sector trends and competitive requirements.

[[36]], [[220]], [[453]]

Ownership & Lock-Up Structure

The post-IPO shareholding structure is well-dispersed, with significant Pre-IPO and cornerstone investor participation and regulatory-compliant public float.

• Major Shareholders: Matrix Partners, Image Frame (Tencent subsidiary), H Capital, Waterwood, Tiantu Entities
• Cornerstone Investors: Health Vision, Kingmed Diagnostics, Mininglamp Technology, Galaxy Dynasty
• Public Float: Approx. 29.98% of total issued shares post-IPO
• Free Float: Approx. 11.47% of issued shares, exceeding listing minimum
• Lock-up: Pre-IPO and cornerstone investors subject to 6-month lock-up post-listing; ESOP shares subject to scheme rules

[[226]], [[227]], [[220]]

Valuation and Peer Comparison

Valuation metrics are provided for the issuer, but peer comparison data is not disclosed in the prospectus.

[[35]], [[36]]

Research & Analyst Opinions

No research opinions or price targets are disclosed within the prospectus.

IPO Allotment Result

No final subscription outcome data is disclosed in the prospectus.

Listing Outlook

Based on disclosed financial improvements, strong cornerstone/institutional participation, robust public and free float, and sector tailwinds, the IPO appears worth subscribing for investors seeking exposure to healthcare innovation and digital transformation. The likely first-day trading range is estimated to be stable to moderately above the offer price, supported by strategic allocations, stabilization mechanisms, and favorable market conditions as described.

Prospectus Access

The prospectus and further information can be obtained at:

• www.hkexnews.hk
• www.distinctclinic.com

How to Apply

Application Channels:

• HK eIPO White Form service (www.hkeipo.hk) for applicants wishing to receive physical share certificates
• HKSCC EIPO channel via brokers or custodians who are HKSCC Participants

Application Window: 9:00 a.m. on January 29, 2026 to 11:30 a.m. on February 3, 2026

Eligibility: Applicants must be 18+, possess a Hong Kong address (for White Form), and be outside the United States

Minimum Application: 50 shares, with payment in full required at time of application

[[493]], [[4]], [[3]], [[500]]